Atara Biotherapeutics, Inc. - Common Stock (ATRA)
Frequently Asked Questions About Atara Biotherapeutics, Inc. - Common Stock (ATRA)
Does Atara Biotherapeutics have any partnerships?
Yes, Atara Biotherapeutics maintains strategic partnerships with several organizations, including collaborations with large pharmaceutical companies and academic institutions. These partnerships are often aimed at enhancing research initiatives, expanding product development capabilities, and advancing clinical trials.
Has Atara Biotherapeutics received any regulatory approvals?
As of the last update, Atara Biotherapeutics has not yet received approval from major regulatory agencies like the FDA for its lead products. However, the company continues to progress in its clinical trial phases and engages in discussions with regulatory bodies to pursue future approvals.
How can investors find information about Atara Biotherapeutics?
Investors can find information about Atara Biotherapeutics through the company's official website, where they publish press releases, investor presentations, and quarterly financial reports. Additionally, financial news platforms and stock market analysis sites provide updates on the company’s performance.
How is Atara Biotherapeutics funded?
Atara Biotherapeutics has secured funding through a combination of public offerings, private investments, and partnerships with other pharmaceutical companies. This funding approach supports their research and development initiatives, enabling the advancement of their product pipelines.
What are Atara's main products?
Atara's lead products include Epstein-Barr Virus (EBV)-specific T-cell immunotherapies designed to treat patients with EBV-associated malignancies, such as post-transplant lymphoproliferative disorder. Their pipelines also explore treatments for other cancers and viral infections, with ongoing development for various conditions, including multiple sclerosis and solid tumors.
What are the challenges facing Atara Biotherapeutics?
Atara Biotherapeutics faces various challenges typical in the biotechnology sector, including the high cost of clinical trials, regulatory hurdles, competition from other therapeutic approaches, and the need to demonstrate the long-term efficacy and safety of its products in patients.
What does Atara Biotherapeutics, Inc. do?
Atara Biotherapeutics, Inc. is a biotechnology company that focuses on the development of innovative immunotherapies for patients with serious diseases, primarily targeting cancer, autoimmune disorders, and viral infections. The company leverages its expertise in T-cell biology and engineering to develop therapies that aim to harness the immune system to fight disease.
What impact does Atara Biotherapeutics aim to have on patients?
Atara Biotherapeutics aims to have a significant positive impact on patients suffering from serious diseases by developing effective immunotherapies that can lead to better health outcomes, improve survival rates, and ultimately enhance the quality of life for individuals living with challenging medical conditions.
What is AT132?
AT132 is one of Atara Biotherapeutics' innovative product candidates, comprising genetically modified T-cells designed to target and attack EBV-infected cells. It is undergoing evaluation for its potential to treat patients with conditions like post-transplant lymphoproliferative disorder and other EBV-related malignancies.
What is the company’s approach to clinical trials?
Atara Biotherapeutics adopts a rigorous and patient-centered approach to clinical trials, aiming to evaluate the safety and efficacy of its therapies. The company conducts Phase I, II, and III clinical trials, working closely with regulatory agencies to ensure compliance and optimal patient care during studies.
What is the company’s mission?
Atara Biotherapeutics aims to transform the lives of patients with significant unmet medical needs by developing cutting-edge therapies that leverage the immune system. Their mission emphasizes innovation and dedication to improving patient outcomes through personalized medical treatments.
What is the corporate governance structure of Atara Biotherapeutics?
Atara Biotherapeutics has a corporate governance structure that includes a Board of Directors responsible for overseeing the management of the company. This governance framework ensures that business practices align with the interests of shareholders and regulatory standards.
What is the significance of the company’s ticker symbol, ATRA?
The ticker symbol ATRA represents Atara Biotherapeutics' common stock, which trades on the Nasdaq stock exchange. The symbol is used by investors to track the company's stock performance and is an identifier for the publicly traded entity.
What role does T-cell therapy play in Atara’s product development?
T-cell therapy is central to Atara Biotherapeutics' product development strategy, as the company harnesses the power of patient-derived T-cells to create personalized immunotherapies. This approach is designed to enhance the body's natural immune response to eliminate cancerous or infected cells.
What therapeutic areas does Atara Biotherapeutics focus on?
The primary therapeutic areas of focus for Atara Biotherapeutics include oncology, specifically cancers associated with viral infections, and autoimmune diseases. By targeting these high-need areas, the company seeks to develop effective treatments that can improve patient survival rates and quality of life.
When was Atara Biotherapeutics founded?
Atara Biotherapeutics was founded in 2012. Since its inception, the company has focused on advancing its research and development efforts to bring new therapies for patients with severe illnesses to market.
Where can I find Atara Biotherapeutics’ financial reports?
Atara Biotherapeutics’ financial reports can be accessed through their official website in the investor relations section. Additionally, reports filed with the U.S. Securities and Exchange Commission (SEC) provide comprehensive financial information and disclosures regarding the company’s performance.
Where is Atara Biotherapeutics headquartered?
Atara Biotherapeutics is headquartered in San Diego, California. This location provides the company with access to a vibrant biotech community, facilitating collaboration and innovation in therapeutic development.
Who are the key executives at Atara Biotherapeutics?
Atara Biotherapeutics is led by a team of experienced executives with expertise in biotechnology and pharmaceuticals. Key leadership typically includes a CEO, CFO, and heads of research and development, operations, and commercial strategy, though specific names can change over time.
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 5.540
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 11:40 am EDT on April 7th, 2025
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 560.11M
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 101.10M shares outstanding.